BUZZ-Absci因脱发药物数据向好而股价上涨
6月24日 - ** 药物研发公司Absci(ABSI.O)的股价在盘前交易中上涨17.9%,至8.74美元
** 该公司公布了 (link) 其利用人工智能开发的实验性药物ABS-201的早期临床试验数据,该药物针对雄激素性脱发(一种常见的脱发类型)
** 该公司表示,来自32名健康成年受试者单次给药的早期数据显示,该药物耐受性良好,截至6月8日未报告任何严重副作用
** 数据显示,ABS-201的估计半衰期至少为65天,这支持了在六个月内进行两到三次注射的可行性
** 该公司计划于今年晚些时候启动针对子宫内膜异位症的ABS-201中期临床试验
** 此外,Absci 定价1亿美元的 (link) 股票发行,该发行由礼来公司( LLY.N)及多家投资机构支持,公司计划将募集资金用于资助 ABS-201在雄激素性脱发和子宫内膜异位症领域的研发
** 截至上一交易日收盘,ABSI股价年内涨幅已超过一倍
At the request of the copyright holder, you need to log in to view this content
LOGIN / SIGN UPDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.